Targeting Allergic Disease at its source.
Cellergy Pharma is developing a first-in-class CAR T cell immunotherapy for treating severe allergic diseases.
Cellergy Pharma is developing a first-in-class CAR T cell immunotherapy for treating severe allergic diseases.
Cellergy Pharma is at the forefront of moving CAR T cells beyond the treatment of cancer, to the treatment of diseases caused by the immune system
Cellergy Pharma’s CAR T cells target and eliminate the cells that cause allergic diseases - IgE-producing cells.
Cellergy Pharma is targeting two large underserved severe allergic disease markets - uncontrollable severe allergic asthma and severe food allergy.
Copyright © 2023 Cellergy Pharma, Inc. - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.